These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.
|Number of pages||9|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Feb 2019|